Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Intangibles (2022 - 2025)

Axsome Therapeutics' Intangibles history spans 4 years, with the latest figure at $63.8 million for Q2 2025.

  • For Q2 2025, Intangibles changed 0.0% year-over-year to $63.8 million; the TTM value through Jun 2025 reached $63.8 million, changed 0.0%, while the annual FY2024 figure was $63.8 million, 19.73% up from the prior year.
  • Intangibles for Q2 2025 was $63.8 million at Axsome Therapeutics, roughly flat from $63.8 million in the prior quarter.
  • Across five years, Intangibles topped out at $63.8 million in Q2 2024 and bottomed at $48.5 million in Q3 2024.
  • The 4-year median for Intangibles is $62.9 million (2022), against an average of $60.1 million.
  • The largest annual shift saw Intangibles dropped 10.69% in 2023 before it rose 19.73% in 2024.
  • A 4-year view of Intangibles shows it stood at $59.7 million in 2022, then fell by 10.69% to $53.3 million in 2023, then grew by 19.73% to $63.8 million in 2024, then changed by 0.0% to $63.8 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Intangibles are $63.8 million (Q2 2025), $63.8 million (Q1 2025), and $63.8 million (Q4 2024).